Literature DB >> 35610990

The Efficacy and Safety of Guselkumab Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Phase 2b QUASAR Study Results Through Week 12.

.   

Abstract

Entities:  

Year:  2022        PMID： 35610990      PMCID： PMC9122071     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  2 in total

1.  Highlights in Ulcerative Colitis From the 17th Congress of the European Crohn's and Colitis Organisation: Commentary.

Authors:  David T Rubin
Journal:  Gastroenterol Hepatol (N Y)       Date:  2022-04

2.  The Efficacy and Safety of Guselkumab Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Phase 2b QUASAR Study Results Through Week 12.

Authors: 
Journal:  Gastroenterol Hepatol (N Y)       Date:  2022-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.